Transgenic Technology for Monoclonal Antibody Production
- 275 Downloads
Monoclonal antibodies account for between one-third and one-half of all pharmaceutical products in development and in human clinical trials. Both the nature of monoclonal antibody therapies, and the relatively large size of the monoclonal antibody molecules dictate that the production requirements for many of these therapeutic monoclonal antibody products will be 100 kilograms or more per year. It is widely acknowledged that there is currently a worldwide shortage of biomanufacturing capacity, and that the gap between biomanufacturing capacity and the active pharmaceutical ingredient material requirements for these products is expected to increase.
KeywordsRecombinant Protein Expression Cassette Nuclear Transfer Unit Production Cost Surrogate Mother
Unable to display preview. Download preview PDF.
- Biotechnology Industry Organization website: www.bio.orgGoogle Scholar
- Li-Chan, E., Powrie, W., and Nakai, S., 1995, The Chemistry of Eggs and Egg Products. In Egg Science and Technology, Fourth Edition (Stadelman, W., and Cotterill, O., eds.), Haworth Press, New York, pp. 105–175.Google Scholar
- Stadelman, W., 1995, Egg-Production Practices. In Egg Science and Technology, Fourth Edition (Stadelman, W., and Cotterill, O., eds.), Haworth Press, New York, pp. 9–37.Google Scholar
- Sugino, H., Nitoda, T., and Juneja, L., 1997, General Chemical Composition of Hen Eggs. In Hen Eggs: Their Basic and Applied Science (Yamamoto, T., Juneja, L., Hatta, H., and Kim, M., eds.), CRC Press, Florida, pp. 13–24.Google Scholar